First Time Loading...

Gritstone bio Inc
NASDAQ:GRTS

Watchlist Manager
Gritstone bio Inc Logo
Gritstone bio Inc
NASDAQ:GRTS
Watchlist
Price: 0.7932 USD -2.42%
Updated: Apr 25, 2024

Intrinsic Value

GRTS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. [ Read More ]

The intrinsic value of one GRTS stock under the Base Case scenario is 0.2914 USD. Compared to the current market price of 0.7932 USD, Gritstone bio Inc is Overvalued by 63%.

Key Points:
GRTS Intrinsic Value
Base Case
0.2914 USD
Overvaluation 63%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Gritstone bio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GRTS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Gritstone bio Inc

Provide an overview of the primary business activities
of Gritstone bio Inc.

What unique competitive advantages
does Gritstone bio Inc hold over its rivals?

What risks and challenges
does Gritstone bio Inc face in the near future?

Has there been any significant insider trading activity
in Gritstone bio Inc recently?

Summarize the latest earnings call
of Gritstone bio Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gritstone bio Inc.

Provide P/S
for Gritstone bio Inc.

Provide P/E
for Gritstone bio Inc.

Provide P/OCF
for Gritstone bio Inc.

Provide P/FCFE
for Gritstone bio Inc.

Provide P/B
for Gritstone bio Inc.

Provide EV/S
for Gritstone bio Inc.

Provide EV/GP
for Gritstone bio Inc.

Provide EV/EBITDA
for Gritstone bio Inc.

Provide EV/EBIT
for Gritstone bio Inc.

Provide EV/OCF
for Gritstone bio Inc.

Provide EV/FCFF
for Gritstone bio Inc.

Provide EV/IC
for Gritstone bio Inc.

Show me price targets
for Gritstone bio Inc made by professional analysts.

What are the Revenue projections
for Gritstone bio Inc?

How accurate were the past Revenue estimates
for Gritstone bio Inc?

What are the Net Income projections
for Gritstone bio Inc?

How accurate were the past Net Income estimates
for Gritstone bio Inc?

What are the EPS projections
for Gritstone bio Inc?

How accurate were the past EPS estimates
for Gritstone bio Inc?

What are the EBIT projections
for Gritstone bio Inc?

How accurate were the past EBIT estimates
for Gritstone bio Inc?

Compare the revenue forecasts
for Gritstone bio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gritstone bio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gritstone bio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gritstone bio Inc compared to its peers.

Compare the P/E ratios
of Gritstone bio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Gritstone bio Inc with its peers.

Analyze the financial leverage
of Gritstone bio Inc compared to its main competitors.

Show all profitability ratios
for Gritstone bio Inc.

Provide ROE
for Gritstone bio Inc.

Provide ROA
for Gritstone bio Inc.

Provide ROIC
for Gritstone bio Inc.

Provide ROCE
for Gritstone bio Inc.

Provide Gross Margin
for Gritstone bio Inc.

Provide Operating Margin
for Gritstone bio Inc.

Provide Net Margin
for Gritstone bio Inc.

Provide FCF Margin
for Gritstone bio Inc.

Show all solvency ratios
for Gritstone bio Inc.

Provide D/E Ratio
for Gritstone bio Inc.

Provide D/A Ratio
for Gritstone bio Inc.

Provide Interest Coverage Ratio
for Gritstone bio Inc.

Provide Altman Z-Score Ratio
for Gritstone bio Inc.

Provide Quick Ratio
for Gritstone bio Inc.

Provide Current Ratio
for Gritstone bio Inc.

Provide Cash Ratio
for Gritstone bio Inc.

What is the historical Revenue growth
over the last 5 years for Gritstone bio Inc?

What is the historical Net Income growth
over the last 5 years for Gritstone bio Inc?

What is the current Free Cash Flow
of Gritstone bio Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gritstone bio Inc.

Financials

Balance Sheet Decomposition
Gritstone bio Inc

Current Assets 87.4m
Cash & Short-Term Investments 79.3m
Receivables 231k
Other Current Assets 7.9m
Non-Current Assets 90.3m
PP&E 84.1m
Other Non-Current Assets 6.2m
Current Liabilities 27.3m
Accounts Payable 3.8m
Accrued Liabilities 21.2m
Other Current Liabilities 2.4m
Non-Current Liabilities 98.6m
Long-Term Debt 40.1m
Other Non-Current Liabilities 58.4m
Efficiency

Earnings Waterfall
Gritstone bio Inc

Revenue
16.3m USD
Operating Expenses
-156m USD
Operating Income
-139.6m USD
Other Expenses
1.1m USD
Net Income
-138.5m USD

Free Cash Flow Analysis
Gritstone bio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

GRTS Profitability Score
Profitability Due Diligence

Gritstone bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
15/100
Profitability
Score

Gritstone bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

GRTS Solvency Score
Solvency Due Diligence

Gritstone bio Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
39/100
Solvency
Score

Gritstone bio Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GRTS Price Targets Summary
Gritstone bio Inc

Wall Street analysts forecast GRTS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GRTS is 5.6 USD .

Lowest
Price Target
Not Available
Average
Price Target
5.6 USD
606% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GRTS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GRTS Price
Gritstone bio Inc

1M 1M
-71%
6M 6M
-58%
1Y 1Y
-67%
3Y 3Y
-92%
5Y 5Y
-93%
10Y 10Y
-94%
Annual Price Range
0.7932
52w Low
0.7366
52w High
2.9
Price Metrics
Average Annual Return 13.55%
Standard Deviation of Annual Returns 125.47%
Max Drawdown -97%
Shares Statistics
Market Capitalization 153.6m USD
Shares Outstanding 193 658 944
Percentage of Shares Shorted 10.49%

GRTS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Gritstone bio Inc Logo
Gritstone bio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

153.6m USD

Dividend Yield

0%

Description

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 193 full-time employees. The company went IPO on 2018-09-28. The firm discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The firm has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

Contact

CALIFORNIA
Emeryville
5959 Horton Street, Suite 300
+15108716100.0
https://gritstonebio.com/

IPO

2018-09-28

Employees

193

Officers

Co-Founder, President, CEO & Director
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Executive VP & COO
Mr. Erin E. Jones M.S.
Executive VP and Head of Research & Development
Dr. Karin Jooss Ph.D.
Executive VP & CFO
Ms. Vassiliki Economides
Chief Accounting Officer
Mr. James Cho
Director of Investor Relations & Corporate Communications
George MacDougall
Show More
Executive VP & Chief People Officer
Ms. Stacy Proctor
Executive VP & Chief Business Officer
Dr. Matthew J. Hawryluk M.B.A., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one GRTS stock?

The intrinsic value of one GRTS stock under the Base Case scenario is 0.2914 USD.

Is GRTS stock undervalued or overvalued?

Compared to the current market price of 0.7932 USD, Gritstone bio Inc is Overvalued by 63%.